Darin Johnson has been the President and CEO of Exactech since January 2020.
Darin joined Exactech in 2002 and has held progressively challenging and elevated marketing positions before being named Senior Vice President of Extremities in 2018. Darin was the original leader of the Equinoxe® shoulder product line at Exactech, which has become the company’s most successful segment. He has built and led cross-functional, global teams of orthopaedic surgeons, product managers, engineers and sales professionals. Prior to joining Exactech, Darin spent five years in the investment banking industry. He holds a bachelor’s degree from Brown University and studied Economics at Oxford University.
Jeffrey R. Binder has been the Chairman of Exactech since January 2020 and previously had been the Co-Executive Chairman since February 2018. He also is Chairman of the Board of Immucor, Inc, where he was President and CEO from June 2015 through January 2018. Jeff is a Senior Advisor for TPG Capital.
Jeff is a 25-year veteran of the medical device and diagnostic industry and previously served as Chief Executive Officer and President of Biomet Inc. from February 2007 until June 2015.
Jeff’s previous positions included a stint as Senior Vice President of Diagnostic Operations of Abbott Laboratories from January 2006 through February 2007. Prior to that he served as President of Abbott Spine from June 2003 until January 2006, and was President and CEO of Spinal Concepts from 2000 until Spinal Concepts was acquired by Abbott Laboratories in June 2003.
Jeff holds a bachelor’s degree in applied mathematics from Yale University and a master’s degree in public affairs from the Woodrow Wilson School at Princeton University.
David W. Petty has been Vice Chairman of the Board of Directors since January 2020.
David previously served as Chief Executive Officer since March 2014 and President of Exactech since November 2007. He also was executive vice president of sales and marketing from February 2000 until December 2007, and served as a member of the Leadership Team, which oversees and directs the company’s operations. Since joining the company in 1988, he was employed in successive capacities in the areas of operations, sales and marketing. He served as Vice President of Operations from April 1991 until April 1993 and Vice President of Marketing from 1993 until 2000. Petty received his B.A. from the University of Virginia in 1988 and completed The Executive Program of the Darden School of Business in 1999.
Todd Sisitsky is the Managing Partner of the TPG Capital business in the North America and Europe, and co-leads the healthcare team for TPG Capital.
Prior to joining TPG in 2003, Todd worked at Forstmann Little & Company and Oak Hill Capital Partners. He received an MBA from the Stanford Graduate School of Business, where he was an Arjay Miller Scholar, and earned his undergraduate degree from Dartmouth College, where he graduated Summa Cum Laude. He has played leadership roles on TPG’s investments in Aptalis, Biomet, Fenwal, Healthscope, IASIS Healthcare, Immucor, IMS Health, Par Pharmaceutical, and Surgical Care Affiliates. Todd also serves on the Campaign for Tobacco-Free Kids Board of Directors as well as the Dartmouth Medical School Board of Overseers.
John Schilling is a Partner and leads the Operations team for TPG Capital in North America and Europe, and co-leads the healthcare team for TPG Capital.
Prior to joining TPG in 2011, John managed Sales and Marketing for the U.S. pharmaceutical business at Abbott and was a Partner at McKinsey & Company. John received his undergraduate degree in Biomedical Engineering from Duke, a Master’s in Biomedical Engineering from Johns Hopkins where he was a Bozzelli Scholar, and an M.D. from the University of Chicago where he received the Joseph A. Capps Award for the most outstanding student in clinical medicine. Thereafter, John conducted his residency training in surgery at Johns Hopkins. While at TPG, John has played leadership roles on TPG’s investments in Adare Pharmaceuticals, Aptalis, Beaver Visitec International, EnvisionRx, Immucor, and Par Pharmaceutical.
Kendall Garrison is with TPG Capital and is based in San Francisco, where he focuses on investments in the healthcare sector.
Kendall serves on the Board of Directors of Exactech and Beaver Visitec International and has also been involved in TPG’s investments in Immucor, Surgical Care Affiliates and Sabre Holdings. Prior to joining TPG in 2008, Kendall worked at Goldman, Sachs & Co. in its investment banking division. Kendall received a BBA with Honors from the University of Wisconsin-Madison and an MBA from Harvard Business School.
Gary J. Miller, Ph.D. is a founder and has been executive vice president of research and development since February 2000.
He was Vice President of Research and Development from 1986 until 2000 and was a director from March 1989 until November 2007. Gary was Associate Professor of Orthopaedic Surgery and Director of Research and Biomechanics at the University of Florida College of Medicine from July 1986 until August 1996. Gary received his Bachelor of Science from the University of Florida, his Master of Science (biomechanics) from Massachusetts Institute of Technology and his Doctor of Philosophy in mechanical engineering (biomechanics) from the University of Florida.
Gary has previously held an adjunct associate professorship in the College of Veterinary Medicine’s Small Animal Surgical Sciences Division and has served as an adjunct associate professor in the Department of Aerospace, Mechanics and Engineering Sciences from 1995 until 2010 at the University of Florida. He currently serves on the Dean’s advisory board in the Wertheim College of Engineering at the University of Florida. He also serves on the College’s external advisory boards for the J. Crayton Pruitt Department of Biomedical Engineering and for the Department of Mechanical and Aerospace Engineering, where he also is appointed as Courtesy Professor. Miller was a consultant to the United States Food and Drug Administration from 1989 to 1992 and has served as a consultant to such companies as Johnson & Johnson Orthopaedics, Dow-Corning Wright and Orthogenesis.
Joel C. (Jody) Phillips, CPA has been Chief Financial Officer of Exactech since July 1998.
Joel C. (Jody) Phillips, CPA has been Chief Financial Officer of Exactech since July 1998 and Treasurer since March 1996. Jody was promoted to Executive Vice President in February 2015. He was Manager, Accounting and Management Information Systems at the company from April 1993 to June 1998. From January 1991 to April 1993, Jody was employed by Arthur Andersen. He received a B.S. and a Masters in Accounting from the University of Florida and is a Certified Public Accountant. During 2008, Jody completed the Advanced Executive Program at the Kellogg School of Management at Northwestern University.
Donna H. Edwards, J.D. became Vice President of Legal in August 2011. She has been employed by Exactech since January 2001.
Donna served as Legal Coordinator from January 2001 to February 2003, Corporate Attorney from February 2003 to April 2011 and as Interim Compliance Officer from April 2011 to August 2011. Previously, she was employed by Exactech as Regulatory Affairs Coordinator from June 1996 to August 1998. Ms. Edwards received her B.S. degree from Duke University and her J.D. degree from the University of Alabama
Bruce Thompson joined the company in 2004 as Senior Vice President, General Manager – Biologics Division and also led Exactech’s Spine Division before becoming Senior Vice President, Strategic Initiatives in February 2018.
Prior to joining Exactech, Bruce spent 22 years with Smith & Nephew in their Orthopaedic Division. During that time, he held various positions within Smith & Nephew, including Vice President – International Sales, Vice President – Product Planning and Launch, Vice President, General Manager – Spine Division, Group Director of Trauma Manufacturing, Director of Materials Management, and held various product and sales management positions. Bruce earned a Bachelor of Science in Accountancy at Miami University, Oxford, Ohio, and completed the Executive MBA program at the University of Memphis in 1989.
Daniel P. (Dan) Hann is a 1977 graduate of California State University, Fullerton where he earned a Bachelor of Arts degree in Economics from the School of Business and Economics.
For the past 25 years Dan has served in a variety of capacities with Biomet, Inc., a medical device manufacturer primarily focused on orthopedic implants. From 1989 to 2006, he served as Biomet’s Senior Vice President & General Counsel and as a member of the Board of Directors. During 2006 and 2007, he served as Biomet’s Interim President & Chief Executive Officer and helped guide the sale of the Nasdaq company in a $11.6 billon private equity transaction which closed in September 2007. Since going private he has been in charge of business development and currently serves as Senior Vice President, Business Development.
Following Dan’s graduation from Cal State Fullerton, he went on to receive his Masters of Science degree in Economics from the University of Illinois. Thereafter he went on to become an Assistant Professor of Economics as well as the Chairman of the Department of Economics & Business at Franklin College in Franklin, Indiana. He also served as an Adjunct Professor of Economics at Indiana University. In 1984, Dan received his law degree from the Indiana University School of Law and left Franklin College to join the Indianapolis law firm of Ice Miller. While with Ice Miller, where his practice was primarily focused on corporate law, intellectual property and commercial litigation, Dan began handling a variety of legal matters for Biomet and joined the company in 1989 as its first General Counsel.
In recent years Dan has testified before Congress on pending legislation and served as a member of The Nasdaq Stock Market Listing & Hearing Review Council and various boards of directors.